Does Cigna Cover Wegovy?
The verdict
Conditional on most plans
Cigna's standard Express Scripts (Evernorth) National Preferred Formulary excludes Wegovy injection and Wegovy tablets for weight loss on the base formulary for 2026 — weight-loss Wegovy requires an employer opt-in beyond the standard NPF. Where employers opt in, participating plans can access an Evernorth $200/month out-of-pocket cap for weight-loss GLP-1s, launched May 21, 2025. ACA/individual plans generally exclude Wegovy for weight loss. Medicare covers the cardiovascular indication only.
Coverage is set by your specific plan and formulary. This is a research summary — always confirm with Cigna using your member ID.
Key facts
Express Scripts' 2026 National Preferred Formulary excludes Wegovy injection and tablets for weight loss; Zepbound vials are the NPF-preferred weight-loss GLP-1.
Express Scripts/Evernorth — 2026 National Preferred Formulary
Evernorth launched a $200/month out-of-pocket cap for weight-loss GLP-1s on participating employer plans on May 21, 2025 — available only to plans that opt in beyond the base NPF.
Evernorth (Express Scripts) — GLP-1 benefit programs, 2025
Medicare Part D cannot cover Wegovy for weight loss by statute; the Medicare GLP-1 Bridge launches July 1, 2026 at $50/month for eligible beneficiaries outside Part D.
CMS.gov — Medicare GLP-1 Weight Loss Drug Access Program
Medicare vs. commercial coverage
Whether Cigna covers Wegovy depends heavily on which kind of plan you hold. They follow completely different rules — here's each one, side by side.
Medicare
Part D & Advantage plans
Cigna Medicare Advantage (Part D) cannot cover Wegovy for weight loss by statute. The cardiovascular risk-reduction indication — for adults with established CVD who are overweight or obese — is coverable under Cigna Medicare Advantage with prior authorization. The Medicare GLP-1 Bridge, launching July 1, 2026 through December 31, 2027, gives eligible beneficiaries weight-loss access to Wegovy at $50/month outside the Part D benefit. The $50 copay does not count toward the $2,100 Part D OOP cap or TrOOP, and Extra Help cannot be applied. Bridge eligibility: BMI ≥35; or ≥30 with heart failure, uncontrolled hypertension, or CKD; or ≥27 with prediabetes, prior MI, prior stroke, or symptomatic PAD. Members already on a Part D-covered GLP-1 are ineligible. NovoCare savings card is not available to Medicare beneficiaries.
Commercial / Employer
Group & marketplace plans
Cigna's commercial pharmacy benefit is administered by Express Scripts (Evernorth). For 2026, the Express Scripts National Preferred Formulary (NPF) excludes Wegovy injection and Wegovy tablets for weight loss; Zepbound vials are the Express Scripts preferred weight-loss GLP-1. On a standard Cigna NPF plan, there is no PA path for weight-loss Wegovy — it is a formulary exclusion, not a prior-authorization hurdle. Employers can opt in to broader weight-loss GLP-1 coverage beyond the base NPF. Where employers do opt in, participating plans can access the Evernorth $200/month out-of-pocket cap for weight-loss GLP-1s — launched May 21, 2025 — which represents substantial savings compared to the $1,349 cash list price. ACA/individual plans generally exclude weight-loss GLP-1s. Commercially insured members whose Cigna plan covers Wegovy may use the NovoCare savings card ($25/month, max $100/28-day supply). Not available to Medicare or Medicaid beneficiaries. Verify whether your employer's plan has opted in by checking the Cigna/Express Scripts formulary or calling Cigna member services.
The 5 boxes you must tick to get approved
Commercial plans that will consider Wegovy require prior authorization. Check off what applies to you to see how close you are — this is a guide, not a guarantee of approval.
Meet all 5 and you have a documented case for approval. Missing any one is the most common reason requests are denied.
Your cost, three ways
What Wegovy actually costs you swings enormously depending on how it's covered. Here's the realistic range.
Paying cash
$1,349/month (Novo Nordisk published list price, 28-day supply). NovoCare self-pay: approximately $349/month for standard injection doses after an introductory period (through December 31, 2026).
List price with no coverage — before any manufacturer savings card.
With coverage
Where the employer opts in: plan-specific cost-share; Evernorth $200/month OOP cap available to participating plans (launched May 21, 2025). NovoCare savings card: commercially insured members whose plan covers Wegovy may pay as little as $25/month (max $100 per 28-day supply). Not available to Medicare or Medicaid beneficiaries.
Typical monthly copay once prior authorization is approved.
Bridge program
Medicare GLP-1 Bridge: $50/month for eligible Medicare beneficiaries from July 1, 2026 through December 31, 2027. Operates outside Part D — does not count toward the $2,100 OOP cap or TrOOP.
Reduced copay through the assistance program, where eligible.
All cost figures are estimates and vary by plan tier and pharmacy. Verify your actual cost-share through the Cigna member portal or by calling Cigna/Express Scripts member services before starting treatment.
Check YOUR exact coverage in 3 steps
General answers only get you so far. Here's how to confirm your own plan's decision in a few minutes.
- 1
Check whether your employer opted in beyond the base Express Scripts NPF
The standard 2026 Express Scripts National Preferred Formulary excludes Wegovy for weight loss. Before assuming coverage, confirm with Cigna member services or the Express Scripts formulary tool whether your specific employer plan has opted in to broader weight-loss GLP-1 coverage. If it has not, there is no PA path for weight-loss Wegovy on the standard NPF.
- 2
Use the Cigna or Express Scripts drug-lookup tool
Visit cigna.com or the Express Scripts member portal with your member ID. Search for 'Wegovy' or 'semaglutide 2.4 mg' to see the current formulary status on your specific plan. If the plan has opted in, the tool will confirm tier placement, PA requirements, and whether the Evernorth $200/month cap applies.
- 3
Work with your prescriber on prior authorization if your plan is opted in
If your employer's plan includes the weight-loss GLP-1 benefit, your prescriber will document your BMI, qualifying comorbidities, and participation in a weight-management program. For Medicare Advantage members seeking the cardiovascular indication, confirm that established CVD is documented in your medical record. Track weight-loss progress — renewals typically require at least 5% documented weight loss.
Options if Cigna won't cover Wegovy
A denial isn't the end of the road. These are the paths people commonly explore next — discuss any of them with your prescriber.
Zepbound (tirzepatide) — preferred on Cigna/Express Scripts base NPF
Zepbound vials are the Express Scripts preferred weight-loss GLP-1 on the 2026 base NPF. If your employer's Cigna plan follows the standard NPF, Zepbound vials may be the covered weight-loss GLP-1 option. Discuss with your prescriber whether Zepbound is appropriate for your situation.
Evernorth $200/month OOP cap (opt-in plans only)
Employers who have opted in to broader weight-loss GLP-1 coverage can offer members an Evernorth $200/month out-of-pocket cap for Wegovy, launched May 21, 2025. Confirm with Cigna whether your plan participates.
NovoCare self-pay program
NovoCare Pharmacy offers Wegovy at approximately $349/month without insurance, after an introductory period. Novo Nordisk has announced list price reductions to approximately $675/month effective January 1, 2027.
Compounded semaglutide
Compounded semaglutide is available without insurance or formulary constraints. See the Curex offer below. Compounded medications are not the same as Wegovy and have not been approved by the FDA.
These options are listed for information only — your own clinician decides what is appropriate for you.
❓Frequently Asked Questions
Cigna's drug benefit runs through Express Scripts, whose 2026 National Preferred Formulary excludes Wegovy injection and Wegovy tablets for weight loss on the base plan — Zepbound vials are the preferred weight-loss GLP-1. Coverage for Wegovy requires an employer opt-in beyond the base NPF. Where employers do opt in, participating plans can access an Evernorth $200/month out-of-pocket cap. Check whether your employer's plan has opted in before pursuing a prior authorization.
Evernorth (Express Scripts' parent) launched a $200/month out-of-pocket cap for weight-loss GLP-1s on participating Cigna employer plans on May 21, 2025. This cap applies to plans that have opted in beyond the base NPF and represents significant savings compared to the $1,349 cash list price. The cap is plan-specific — not all Cigna employer plans participate. Verify with Cigna member services whether your plan includes this program.
Express Scripts made Zepbound vials (tirzepatide) the preferred weight-loss GLP-1 on its 2026 National Preferred Formulary, excluding Wegovy injection and tablets as non-preferred alternatives. This is a PBM formulary positioning decision based on rebate negotiations between Express Scripts and the manufacturers. It means that on a standard Cigna NPF plan, a prescription for Zepbound may be coverable where one for Wegovy is not. Discuss with your prescriber whether Zepbound is a suitable option for your situation.
Cigna and Aetna take opposite approaches: Aetna's PBM is CVS Caremark, which made Wegovy the preferred weight-loss GLP-1 effective July 1, 2025 — commercially insured Aetna members can access Wegovy with PA (BMI ≥35 required). Cigna's PBM, Express Scripts, excludes Wegovy on the base NPF and prefers Zepbound vials instead. This CVS Caremark-prefers-Wegovy versus Express Scripts-excludes-Wegovy contrast is the sharpest PBM split in the GLP-1 coverage landscape.
No. Cigna Medicare Advantage (Part D) cannot cover Wegovy for weight loss by statute. Cigna Medicare Advantage can cover Wegovy for cardiovascular risk reduction in adults with established CVD with prior authorization. Starting July 1, 2026, eligible Medicare beneficiaries can access Wegovy for weight loss at $50/month through the Medicare GLP-1 Bridge, operating outside Part D. The $50 Bridge copay does not count toward the $2,100 Part D OOP cap.
Related Articles
Does BCBS North Carolina Cover Wegovy? 2026 | Curex
BCBS North Carolina: NC State Health Plan dropped weight-loss GLP-1s in 2024; NC Medicaid removed obesity coverage October 2025. Verify your specific plan.
Read moreDoes BCBS of Arizona Cover Wegovy? 2026 Guide | Curex
BCBS of Arizona covers Wegovy only where your employer opted in; formulary not published. Verify via drug-lookup and confirm with HR first.
Read moreDoes Blue Cross Blue Shield Cover Wegovy? 2026 | Curex
BCBS is 33+ independent affiliates — no single Wegovy answer. Trend favors exclusion in 2025-2026. Find your affiliate and verify your formulary.
Read moreDoes Blue Cross Blue Shield of Illinois Cover Wegovy? | Curex
BCBS Illinois (HCSC) covers Wegovy only where your employer opts in. ACA plans exclude it. Formulary not public — verify on your plan's drug-lookup tool.
Read moreDoes BCBS Alabama Cover Wegovy? 2026 Guide | Curex
BCBS Alabama Wegovy coverage is employer-dependent and unpublished. Alabama Medicaid excludes obesity GLP-1s. How to verify your specific plan.
Read moreDoes Blue Shield of California Cover Wegovy? | Curex
Blue Shield of CA limits new Wegovy weight-loss starts to BMI 40+ since Jan 2025. Below that threshold, weight-loss coverage is excluded. Verify your plan.
Read moreWhether or not Cigna covers Wegovy, there's a path that skips insurance
Cigna's Express Scripts formulary excludes Wegovy for weight loss on the base plan. For patients whose employer didn't opt in, Curex offers compounded semaglutide from $49/mo (compounded tirzepatide from $149/mo) — no insurance, no prior authorization. Compounded semaglutide is not the same medication as Wegovy. Prescription required, subject to provider review.
- Medication + free shipping
- 24/7 provider access
- Medical intake & prescription review
Compounded semaglutide and tirzepatide are not the same medications as Wegovy and are not branded or FDA-approved products. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.
This content is for informational purposes only and does not constitute medical, financial, or insurance advice. Coverage rules, prior-authorization criteria, and copay amounts change frequently and vary by plan, formulary tier, and effective date — always verify current benefits directly with Cigna before making any decision. Consult a licensed healthcare provider and your plan administrator for guidance specific to your situation. Curex offers compounded semaglutide and tirzepatide, which are not the same medications as Wegovy and are not branded or FDA-approved products; prescription required, subject to provider review. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.